Combined nivolumab and ipilimumab or monotherapy in untreated melanoma

New England Journal of Medicine

Volumn 373, Issue 13, 2015, Pages 1270-1271

  Valsecchi, Matias E ^a  

^a Huntington Internal Medicine Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER GRADING; CANCER MORTALITY; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; LETTER; MELANOMA; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSPECIFIED SIDE EFFECT; FEMALE; MALE; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MELANOMA; SKIN NEOPLASMS;

EID: 84942430653     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1509660     Document Type: Letter

References (3)

1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
2. Hodi FS, Postow MA, Chesney JA, et al. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. Presented at the ASCO Annual Meeting, Chicago, May 29-June 2, 2015. abstract.
3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16.